HUTCHMED
A sharper focus on the path to profitabilityHUTCHMED
Fruquintinib should continue to bear fruitHUTCHMED
FRESCO-2 data support broad uptake in later-line mCRCHUTCHMED
Rich and diverse pipeline with multiple waves of growthHUTCHMED
On the right trackHUTCHMED
A genuinely global R&D-driven biopharma businessHUTCHMED
Strategic collaboration for Tazverik in Greater ChinaHUTCHMED
ASCO 2021: Moving towards combinationsHUTCHMED
Hong Kong listing number 13 is a potent symbolHUTCHMED
≥$600m Hong Kong IPO and global offer (104m shares)